Bayer secures 3 billion euro investment from Apollo for contraceptive business

Bayer has secured 3.0 billion euros in equity capital from Apollo to strengthen its balance sheet, addressing liquidity pressures from Roundup litigation.

Objective Facts

Bayer has secured 3.0 billion euros in equity capital by signing an agreement with global asset management firm Apollo on Friday, July 10, 2026. Apollo-managed funds and affiliates will obtain a minority, non-controlling stake in a newly established entity holding Bayer's long-acting reversible contraceptives (LARC) business, while Bayer will retain a majority stake and continue to exercise complete operational control. The LARC business's primary asset is the Mirena family of products, which generated sales of €1.37 billion in 2025. Bayer will use the funds raised to help cover its ballooning litigation costs tied to the herbicide Roundup. The transaction is expected to close in the third quarter of 2026, subject to approval by antitrust authorities and customary closing conditions.

Deep Dive

Bayer has been weighed down by litigation tied to its Roundup product, with litigation costs already exceeding $10 billion. The company moved to separate its US glyphosate business, which includes the herbicide, into a separate business unit after a favorable Supreme Court ruling. The current Apollo deal represents a structured equity solution — not a full sale — that allows Bayer to raise capital while retaining operational control. For Apollo, the investment operates economically as a form of preferred financing: a minority position without control but with predictable returns from a business with stable revenues, a deal structure that has become standard for large private-equity firms. CFO Judith Hartmann framed the move as generating financial flexibility to refinance maturing bonds and cover the multibillion-dollar legal legacy from Roundup lawsuits in the United States. The transaction addresses near-term liquidity requirements arising from bond maturities and ongoing Roundup litigation costs, while preserving Bayer's ability to continue executing its pharmaceutical growth strategy. The deal's structuring ensures that because Bayer retains control, the LARC entity remains fully consolidated in Bayer's financial statements—preventing the appearance of a divestiture while securing fresh capital. Germany's Bundestag on Friday passed the GKV-Beitragssatzstabilisierungsgesetz — a sweeping healthcare cost-containment law that targets €18.8 billion in savings from 2027, adding longer-term pressure on Bayer's pharma division. An August 19 Roundup settlement fairness hearing will determine whether the company can put a significant portion of its legal exposure behind it; with the stock already at elevated levels and volatility high, any further delay in the courtroom could trigger a swift pullback. The Apollo capital provides a financial cushion but does not eliminate the underlying legal and regulatory headwinds Bayer faces.

Regional Perspective

German business media report that Bayer takes Apollo as a minority shareholder for its contraceptive business, with Apollo investing 3 billion euros in equity into a new entity holding Bayer's LARC business; the move is described as improving capital structure while Bayer retains full operational control over the core pharma business. German press emphasizes the billing and structural sophistication: Bayer establishes a separate entity for long-acting reversible contraceptives; Apollo acquires a non-controlling stake and transfers 3 billion euros, but because Bayer retains voting control and operational leadership, the subsidiary remains fully consolidated in the group's financial statements. German coverage contextualizes the deal within twin external pressures Bayer navigates: on the home front, Germany's Bundestag on Friday passed the GKV-Beitragssatzstabilisierungsgesetz — a sweeping healthcare cost-containment law targeting €18.8 billion in savings from 2027. The pharmaceutical industry fears the real blow will come from tighter price caps and rebate rules, and the sector has warned of potential investment cuts, a risk that weighs on long-term margin expectations for Bayer's pharma division. German media thus frame the Apollo deal not only as a response to Roundup litigation but as a balance-sheet fortification in anticipation of domestic healthcare regulation that will pressure margins industry-wide.

OBJ SPEAKING

Create StoryTimelinesVoter ToolsRegional AnalysisPolicy GuideAll StoriesCommunity PicksUSWorldPoliticsBusinessHealthEntertainmentTechnologyAbout

Bayer secures 3 billion euro investment from Apollo for contraceptive business

Bayer has secured 3.0 billion euros in equity capital from Apollo to strengthen its balance sheet, addressing liquidity pressures from Roundup litigation.

Jul 10, 2026
What's Going On
  • On July 10, 2026, Bayer signed an agreement with global asset management firm Apollo to secure 3.0 billion euros in equity capital.
  • Apollo-managed funds will obtain a minority, non-controlling stake in a newly established entity holding Bayer's long-acting reversible contraceptives (LARC) business, while Bayer retains majority and complete operational control.
  • The primary LARC asset is the Mirena family of products, which generated sales of €1.37 billion in 2025.
  • Bayer will use the funds raised to help cover its ballooning litigation costs tied to the herbicide Roundup.
  • The transaction is expected to close in the third quarter of 2026, subject to approval by antitrust authorities and customary closing conditions.
Region says: German business media (Wirtschaftswoche, Apotheke-Adhoc) report Apollo invests 3 billion euros into a new entity holding Bayer's LARC business, with Bayer retaining full operational control over the core pharma division. German coverage emphasizes the deal's structural mechanics—how minority equity financing allows capital raising without operational loss—and situates the move within Germany's broader healthcare cost-containment pressures.
Objective Deep Dive

Bayer has been weighed down by litigation tied to its Roundup product, with litigation costs already exceeding $10 billion. The company moved to separate its US glyphosate business, which includes the herbicide, into a separate business unit after a favorable Supreme Court ruling. The current Apollo deal represents a structured equity solution — not a full sale — that allows Bayer to raise capital while retaining operational control. For Apollo, the investment operates economically as a form of preferred financing: a minority position without control but with predictable returns from a business with stable revenues, a deal structure that has become standard for large private-equity firms.

CFO Judith Hartmann framed the move as generating financial flexibility to refinance maturing bonds and cover the multibillion-dollar legal legacy from Roundup lawsuits in the United States. The transaction addresses near-term liquidity requirements arising from bond maturities and ongoing Roundup litigation costs, while preserving Bayer's ability to continue executing its pharmaceutical growth strategy. The deal's structuring ensures that because Bayer retains control, the LARC entity remains fully consolidated in Bayer's financial statements—preventing the appearance of a divestiture while securing fresh capital.

Germany's Bundestag on Friday passed the GKV-Beitragssatzstabilisierungsgesetz — a sweeping healthcare cost-containment law that targets €18.8 billion in savings from 2027, adding longer-term pressure on Bayer's pharma division. An August 19 Roundup settlement fairness hearing will determine whether the company can put a significant portion of its legal exposure behind it; with the stock already at elevated levels and volatility high, any further delay in the courtroom could trigger a swift pullback. The Apollo capital provides a financial cushion but does not eliminate the underlying legal and regulatory headwinds Bayer faces.